Benzinga | Nov 5, 2021 09:36AM EDT

SVB Leerink Maintains Outperform on NeoGenomics, Lowers Price Target to $60

SVB Leerink analyst Puneet Souda maintains NeoGenomics (NASDAQ:NEO) with a Outperform and lowers the price target from $63 to $60.